Literature DB >> 3652039

Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.

B S Reddy1, H Maruyama, G Kelloff.   

Abstract

The effect of four dose levels of piroxicam administered during different stages of colon tumor development was studied in male F344 rats to obtain a data base on the efficacy of piroxicam as an inhibitor of colon carcinogenesis. Piroxicam was added at levels of 25, 50, 75, and 150 ppm to the NIH-07 open-formula diet and fed to male F344 rats starting 1, 13, and 23 wk after the carcinogen administration. At 7 wk of age, while the animals were consuming the control diet, all animals except the vehicle-treated controls were given s.c. injection of azoxymethane (CAS:25843-45-2; 29.6 mg/kg body weight, once) to induce intestinal tumors. Forty wk after AOM injection, all animals were necropsied, and tumor incidences were compared among the various dietary groups. Colon tumor incidence (percentage of animals with tumors) was inhibited in a dose-dependent manner in rats fed the diets containing 25, 50, 75, and 150 ppm piroxicam starting 1 and 13 wk after carcinogen treatment. The colon tumor incidences in animals fed the diets containing 0, 25, 50, 75, and 150 ppm of piroxicam starting at 1 wk after carcinogen treatment were 89, 61, 58, 50, and 39%, respectively. When the diets containing 0, 25, 50, 75, and 150 ppm were fed 13 wk after carcinogen treatment, the colon tumor incidences were 89, 69, 69, 44, and 33%, respectively. Colon tumor multiplicity (tumors/animal; tumors/tumor-bearing animal) was also significantly inhibited in animals fed the diets containing 25 to 150 ppm piroxicam starting 1 and 13 wk after carcinogen administration. The number of colon tumors/animal was inhibited by about 80 to 84% in animals fed the 150 ppm piroxicam diet. When the diets containing different levels of piroxicam were fed 23 wk after carcinogen treatment, the colon tumor incidence was significantly inhibited in animals fed the 75 and 150 ppm piroxicam diets. The colon tumor incidences in animals fed the diets containing 0, 25, 50, 75, and 150 ppm were 89, 78, 67, 64, and 64%, respectively. The colon tumor multiplicity (colon tumors/animal) was slightly but significantly inhibited in animals fed the diets containing 25 to 150 ppm piroxicam. The results of this study demonstrate that increasing levels of piroxicam in the diet, when fed 1 or 13 wk after carcinogen insult, inhibit colon tumor incidence in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; M Wada; J U Lee; K Fujimoto; S Tsuji; S Nakajima; R Doi; M Imamura
Journal:  Int J Pancreatol       Date:  1999-10

Review 3.  Chemoprevention of colon cancer by dietary fatty acids.

Authors:  B S Reddy
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 4.  Aspirin, NSAIDs, and digestive tract cancers.

Authors:  M J Thun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 5.  Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk elderly patients?

Authors:  M I Koutsos; S J Shiff; B Rigas
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

Review 6.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

7.  Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Authors:  Ronald A Lubet; James M Scheiman; Ann Bode; Jonathan White; Lori Minasian; M Margaret Juliana; Daniel L Boring; Vernon E Steele; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2015-03-11

8.  Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.

Authors:  S Pugh; G A Thomas
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 9.  RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Authors:  Antonio Strillacci; Cristiana Griffoni; Maria Chiara Valerii; Giorgia Lazzarini; Vittorio Tomasi; Enzo Spisni
Journal:  J Biomed Biotechnol       Date:  2010-06-13

Review 10.  Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer.

Authors:  D Turner; H J Berkel
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.